Clinical trials
Lung Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting lung cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,800 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05492123RecruitingPhase 2
Nivolumab plus ipilimumab with chemoradiation for cervical cancer
This Phase 2 study tests whether adding immunotherapy (nivolumab and ipilimumab) to standard chemoradiation can improve treatment for cervical cancer. It may help by training the immune system to better target cancer cells while radiation and chemotherapy work in the body.
Fortaleza, CearáAges 18–95 - NCT06165900RecruitingPhase 2
Radiation plus immunotherapy and chemo before surgery for triple-negative breast cancer
This trial tests combining stereotactic radiation therapy with immunotherapy (adebrelimab) and chemotherapy (nab-paclitaxel and carboplatin) before surgery for early or locally advanced triple-negative breast cancer. The goal is to see if this combination improves treatment response.
Shenyang, LiaoningAges 18–75 - NCT06190639RecruitingPhase 2
Sintilimab after surgery for node-positive esophageal cancer
This trial tests whether giving the immunotherapy drug Sintilimab after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes and who have already had their tumor removed.
Hangzhou, ZhejiangAges 18 years+ - NCT06201065RecruitingPhase 3
Targeted therapy and immunotherapy for advanced liver cancer
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
Guangzhou, GuangdongAges 18–75 - NCT06166888RecruitingPhase 1
Study of AK131 for advanced solid tumors
This trial tests a new drug called AK131 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and can help slow or shrink the cancer.
Jinan, ShandongAges 18 years+ - NCT06211790RecruitingPhase 2
Targeted first-line treatment for advanced kidney cancer based on protein profile
This trial tests a first-line precision treatment for clear cell kidney cancer that has spread or cannot be removed. It aims to match the treatment to your cancer's protein profile to improve outcomes.
ShanghaiAges 18–75 - NCT05918094RecruitingPhase 3
Testing new chemo plan plus immunotherapy for stomach cancer
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT02215889RecruitingPhase 1/Phase 2
Partial liver transplant for colon or rectal cancer spread to liver
This trial tests whether transplanting part of the liver can help people with colon or rectal cancer that has spread to the liver but cannot be removed with surgery. It also aims to make sure the cancer is limited mainly to the liver and that you are healthy enough for major treatment.
OsloAges 18 years+ - NCT05678270RecruitingPhase 2
ICP-192 for FGFR2 fusion bile duct cancer that spread
This Phase 2 trial tests a medicine called ICP-192 in people with intrahepatic bile duct cancer that cannot be removed with surgery and has spread. It is for tumors that have an FGFR2 fusion/rearrangement, especially after prior chemotherapy stopped working.
Hefei, AnhuiAges 18 years+ - NCT06277024Recruiting
Combination therapy for advanced HER2-negative stomach cancer
This trial tests a combination of immunotherapy (candenizumab), a targeted therapy (lenvatinib), and chemotherapy (SOX regimen) for advanced HER2-negative stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination is safe and works better than standard treatments.
Fuzhou, FujianAges 18–75 - NCT07869823RecruitingEarly Phase 1
Skin cancer treatment for head and neck
This trial tests a combination of an immunotherapy drug (cemiplimab) and a special kind of radiation for a type of skin cancer called cutaneous squamous cell carcinoma. It is designed for people whose cancer has come back or is hard to treat with standard surgery or radiation.
St Louis, MissouriAges 18 years+ - NCT06318559Recruiting
3D augmented reality vs. standard robot prostate surgery
This trial tests whether adding a 3D augmented-reality model to standard robot-assisted prostate surgery can help doctors remove the cancer while better preserving sexual function. It is for men whose MRI shows the cancer may have slightly spread outside the prostate.
Candiolo, TurinAges 40–99 - NCT06314906RecruitingPhase 3
Acupuncture plus anti-nausea drugs for breast cancer chemo side effects
This trial tests whether adding electroacupuncture (a type of acupuncture with mild electrical pulses) to standard anti-nausea medicine can better prevent nausea and vomiting caused by strong chemotherapy. It is for people with early-stage breast cancer who are about to start a very strong chemotherapy regimen.
Lanzhou, GansuAges 18–75 - NCT06330909Recruiting
Focused radiation boost for prostate cancer
This trial tests a newer, more precise radiation treatment that gives a higher dose to the main tumor while keeping radiation to the rest of the prostate the same. It is for men with intermediate- or high-risk prostate cancer who haven't had prior prostate radiation or removal.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT03973671Recruiting
Collecting blood and tissue samples during bladder cancer surgery
This study collects clinical and tissue samples from people who are having surgery for bladder cancer and related urinary-tract tumors. It aims to improve understanding of cancer and may help future care by building a large research dataset.
Leuven, Vlaams-BrabantAges 18–90 - NCT04641936Recruiting
Urine tests to predict response to immunotherapy in bladder cancer
This study uses urine “omics” tests (detailed lab patterns from urine) to predict whether immunotherapy will work for people with metastatic urothelial (bladder/urinary tract) cancer. It may help doctors choose the right treatment sooner by identifying who is more likely to benefit.
TaipeiAges 20 years+ - NCT06360042RecruitingPhase 2
Immunotherapy plus anti-angiogenic drugs for advanced liver cancer
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06385990RecruitingPhase 2
Utidelone plus Capecitabine for residual triple-negative breast cancer
This trial tests a combination of two oral chemotherapy drugs (Utidelone and Capecitabine) for women with triple-negative breast cancer that did not fully disappear after standard chemo before surgery. The goal is to see if this treatment can lower the chance of the cancer coming back.
Changsha, HunanAges 18–70 - NCT03588286Recruiting
Check heart rhythm risk early after a heart attack
This trial tests whether a programmed heart rhythm test can better identify who needs an implanted defibrillator (ICD) soon after a heart attack. It may help prevent dangerous fast heart rhythms (tachyarrhythmias) by guiding who gets an ICD.
Boston, MassachusettsAges 18–85 - NCT06397222RecruitingPhase 2
Combination therapy for advanced liver cancer
This trial tests a combination of three treatments: an immunotherapy drug (Sintilimab), a targeted therapy (Bevacizumab), and a type of internal radiation (SIRT) for people with intermediate or advanced liver cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06405217Recruiting
Recombinant TSH for radioactive iodine therapy in thyroid cancer
This trial tests whether a medicine called recombinant human thyroid stimulating hormone (rhTSH) can help prepare your body for radioactive iodine (131I) treatment, which aims to destroy any remaining or spreading thyroid cancer cells. It may be a good option if your thyroid cancer has come back or spread and you are able to have radioactive iodine therapy.
Nanjing, JiangsuAges 18–75 - NCT06214598Recruiting
Anti-inflammatory diet for breast cancer patients on hormone therapy
This study tests whether a special anti-inflammatory diet can help reduce side effects in breast cancer survivors who are taking aromatase inhibitors after menopause. You would be randomly assigned to either follow the diet for 6 months or continue your usual diet, and your health will be monitored.
BelgradeAges 45–70 - NCT06406634RecruitingPhase 2
Cadonilimab, Lenvatinib, and HAIC for Unresectable Liver Cancer
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
Changsha, HunanAges 18–75 - NCT06410092RecruitingPhase 1
Safety study of FTL001 for advanced solid tumors
This trial tests a new drug called FTL001 for people with advanced solid tumors that have not improved with standard therapy. The goal is to see if it is safe and how well it works.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,800 recruiting lung cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.